Wall Street brokers expect Scholar Rock Holding Co (NASDAQ: SRRK – Get Rating) to earn $1.02 per share for the current fiscal quarter, Zacks Investment Research reports. Zero Analysts have released ScholarRock’s earnings estimates. The lowest estimate for EPS is ($1.17) and the highest estimate is ($0.86). Scholar Rock reported earnings of $0.84 per share in the same quarter last year, indicating a negative annual growth rate of 21.4%. The company is expected to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect ScholarRock to report full-year earnings ($3.16) per share for the current fiscal year, with EPS estimates ranging from ($3.96) to ($2.71). For the next year, analysts expect the company to report earnings of $3.36 per share, with EPS estimates ranging from $3.99 to $2.42. Average earnings per share from Zacks Investment Research is an average based on a survey of sell-side analysts covering Scholar Rock.
Scholar Rock (NASDAQ: SRRK – Get Rating) released its latest quarterly earnings data on Monday, March 7. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.08. ScholarRock has a net negative margin of 236.95% and a negative return on equity of 59.99%. The company generated $4.05 million in revenue for the quarter, compared to the consensus estimate of $4.33 million. During the same period in the previous year, the company ($2.81) earned earnings per share.
A number of research analysts recently commented on SRRK’s stock. Wedbush lowered its price target for Scholar Rock shares from $50.00 to $33.00 and assigned a “na” rating to the stock in a research report on Tuesday, May 17th. Zacks Investment Research upgraded shares of ScholarRock from a “hold” rating to a “buy” rating and set a $6.50 target price per share in a research report on Wednesday, May 11th. HC Wainwright began covering shares of Scholar Rock in a research report on Wednesday, March 23rd. They have assigned a “buy” rating and a $24.00 target price per share. BMO Capital Markets lowered its price target for ScholarRock shares from $74.00 to $55.00 in a research report on Tuesday, May 17. Finally, Piper Sandler lowered its target price for Scholar Rock shares from $56.00 to $28.00 and assigned an “overweight” rating to the stock in a report released on Monday, May 16. One analyst has rated the stock with a hold rating and three analysts have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, ScholarRock currently has an average rating of “Buy” and an average price target of $29.08.
Institutional investors and hedge funds have recently bought and sold shares of stock. TD Asset Management Inc. Its stake in ScholarRock increased 28.9% in the fourth quarter. TD Asset Management Inc. Now 148,964 shares of the company’s stock are valued at $3,700,000 after acquiring an additional 33,393 shares last quarter. BlackRock Inc. increased its stake in ScholarRock by 0.9% during the third quarter. BlackRock now owns 2,198,105 shares of the company’s stock valued at $72,582,000 after purchasing an additional 19,049 shares during the last quarter. IndexIQ Advisors LLC increased its stake in Scholar Rock by 11.1% during the third quarter. IndexIQ Advisors LLC now owns 8,875 shares of the company’s stock, valued at $293,000 after purchasing an additional 889 shares during the last quarter. Wellington Management Group LLP increased its stake in Scholar Rock by 124.9% during the third quarter. Wellington Management Group LLP now owns 1,276,488 shares of the company’s stock valued at $42,150,000 after purchasing an additional 708,831 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Scholar Rock by 3.7% during the third quarter. Geode Capital Management LLC now owns 429,137 shares of the company’s stock valued at $14,170,000 after purchasing an additional 15,207 shares during the last quarter. 84.22% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ SRRK traded down $0.06 during Monday’s trading, to $5.23. 2,416 shares were traded from the exchange, compared to an average volume of 380,863 shares. The 50-day moving average is $9.88 and the 200-day moving average is $17.93. ScholarRock recorded a twelve-month low at $4.84 and a 12-month high at $44.95. The company’s quick ratio is 4.13, the trading ratio is 6.85, and the debt-to-equity ratio is 0.25. The company has a market capitalization of $184.63 million, a price-earnings ratio of -1.73 and a beta of 0.60.
About Scholar Rock (Get Rating)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of drugs to treat critical diseases in which signaling by protein growth factors plays an essential role. The company has developed Apitegromab, a latent myostatin activation inhibitor that has completed a Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which is in phase I clinical trials to treat cancers resistant to checkpoint inhibitory therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Get a FREE copy of Zacks’ Scholar Rock (SRRK) Research Report
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Receive Scholar Rock Daily news and reviews Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Scholar Rock and related companies with MarketBeat.com’s free daily email newsletter.